OOCUITY
LIVE

Serial Number

99180527

Owner

NANOBIOTIX

Attorney

Arturo Perez-Guerrero

Filing Date

May 12, 2025

Add to watchlist:

No watchlists yet
View on USPTO

OOCUITY Trademark

Serial Number: 99180527

OOCUITY is a trademark filed by NANOBIOTIX on May 12, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

NANOBIOTIX (28 trademarks)

60 rue de Wattignies

Entity Type: 99

Trademark Details

Filing Date

May 12, 2025

Registration Date

Not Registered

Goods & Services

Scientific and technological services, namely, research and design services, in the field of nanomedicine, namely, nanotechnology applied to medicine; Biological research; Design and development of new products for third parties; Chemical analysis; Research in the field of chemistry; Neuroscience research; Radiobiology research

Pharmaceutical products for medical use for the treatment of psychiatric diseases and disorders; Pharmaceutical preparation for the diagnosis and treatment of brain diseases and disorders; Pharmaceutical preparation for medical use for the treatment of Parkinson's disease, Alzheimer's disease, epilepsy and all types of neurological and neuropsychiatric disorders and diseases; Pharmaceutical preparation for medical use for the treatment of symptoms of Parkinson's disease, symptoms of Alzheimer's disease, symptoms of epilepsy and symptoms linked to all types of neurological and neuropsychiatric disorders and diseases; Pharmaceutical preparation for the diagnosis and treatment of neurological disorders and diseases for use with deep brain stimulation, transcranial electrical stimulation, transcranial direct current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation including light, magnetic field, electric field, radio frequency or ultrasound stimulation; Nanoparticles for medical use, namely, nanomaterial-based chemical preparations for medical and pharmaceutical purpose for the treatment of central nervous system disorder; Chemical reagents for medical use; Chemical preparations for medical or pharmaceutical use , namely, for the treatment of central nervous system disorders; Diagnostic preparations for medical purposes; Medicines for human medicine, namely, medical preparations for the treatment of central nervous system disorders; Pharmaceutical products for the treatment of central nervous system disorders

Surgical devices and instruments, in particular for the diagnosis and treatment of tumors; Surgical apparatus and instruments, in particular for the diagnosis and treatment of cerebral diseases and disorders; Surgical devices and instruments for use with deep brain stimulation, transcranial electrical stimulation, transcranial direct current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation including light, magnetic field, electric field, radiofrequency or ultrasound stimulation; Drug delivery agents in the form of dissolvable films that facilitate the delivery of therapeutic and diagnostic agents; medical microsyringes that facilitate the delivery of therapeutic and diagnostic agents; Medical device for recording cerebral electrical activity, namely, electrodes, electroencephalograph, microelectrode arrays

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 5, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 5, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jan 5, 2026 CNSL
EXAMINER'S AMENDMENT ENTERED
Jan 5, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 5, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 5, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 5, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 21, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Sep 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Sep 26, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 25, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 21, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
May 12, 2025 MAFR
NEW APPLICATION ENTERED
May 12, 2025 NWAP